Rituximab in Steroid-Dependent Podocytopathies

Rituximab (RTX) seems to be an effective treatment alternative in primary forms of MCD and FSGS, particularly in cases of steroid dependence and frequent relapses. Our findings support the use of RTX for a steroid-free remission in podocytopathies and suggest that maintenance RTX is well-tolerated and associated with prolonged remission. Further studies are needed to confirm its efficacy and safety and establish the optimal induction and maintenance RTX regimen in steroid-dependent podocytopathies.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Rituximab in Steroid-Dependent Podocytopathies ; volume:4 ; number:1 ; year:2024 ; pages:129-136 ; extent:8
Glomerular Diseases ; 4, Heft 1 (2024), 129-136 (gesamt 8)

Creator
Costa, Cláudia
Antunes, Amélia
Oliveira, João
Pereira, Marta
Godinho, Iolanda
Fernandes, Paulo
Jorge, Sofia
Lopes, José António
Gameiro, Joana

DOI
10.1159/000539922
URN
urn:nbn:de:101:1-2412260109196.029145747586
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Associated

  • Costa, Cláudia
  • Antunes, Amélia
  • Oliveira, João
  • Pereira, Marta
  • Godinho, Iolanda
  • Fernandes, Paulo
  • Jorge, Sofia
  • Lopes, José António
  • Gameiro, Joana

Other Objects (12)